DIALOG SEMICONDUCTOR Plc.
- WKN: 927200
- ISIN: GB0059822006
- Land: United Kingdom
Nachricht vom 09.04.2021 | 17:28
Dialog Semiconductor Plc.: Recommended Cash Acquisition of Dialog Semiconductor Plc by Renesas Electronics Corporation - Results of Court Meeting and Dialog General Meeting
Dialog Semiconductor Plc. / Key word(s): AGM/EGM
London, 9 April 2021 - Dialog Semiconductor Plc ("Dialog" or the "Company") is pleased to announce that at the Court Meeting and the Dialog General Meeting of Dialog Shareholders held earlier today in connection with the recommended cash offer made by Renesas for the entire issued and to be issued share capital of Dialog (the "Acquisition") to be effected by means of a scheme of arrangement under Part 26 of the Companies Act (the "Scheme"), all the resolutions proposed were duly passed (without amendment) by the requisite majorities.
Further details, including the number of votes cast for (and against) the relevant resolutions at the Court Meeting and the Dialog General Meeting, will be announced by the Company as soon as practicable and will be made available in due course on Dialog's website at https://www.dialog-semiconductor.com/acquisition-microsite.
Director, Investor Relations
Information and Explanation of the Issuer to this News:
Completion of the Acquisition remains subject to the satisfaction or waiver of the other Conditions set out in the Scheme Document, including (but not limited to) certain competition and regulatory approvals in, inter alia, Germany, the People's Republic of China, Taiwan and the United States, as well as the Court sanctioning the Scheme at the Court Sanction Hearing. The Scheme is expected to become effective in the second half of 2021.
Dialog Semiconductor Plc
phone: +49 (0) 1727 226 409
phone: +44 (0) 1793 756 961
|Company:||Dialog Semiconductor Plc.|
|Tower Bridge House, St. Katharine's Way|
|E1W 1AA London|
|Phone:||+49 7021 805-412|
|Fax:||+49 7021 805-200|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London|
|EQS News ID:||1183139|
|End of Announcement||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
02. Dezember 17:25 Xiaomi: Darum wird es immer teurer
02. Dezember 17:40 Cardano mit Kurssprung – kommt jetzt der Befreiungsschlag?
02. Dezember 18:02 Uber-Rivale Grab: Ein denkbar schlechter Auftakt
02. Dezember 19:02 Lufthansa: Böse Erinnerungen werden wach
02. Dezember 19:26 Alphabet: Dank Cloud Kurspotenzial von 40 Prozent
News im Fokus
Allianz SE: Neufassung der Dividendenpolitik der Allianz SE
02. Dezember 2021, 20:33
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021